NYSE:SQZ

SQZ Biotechnologies Competitors

$13.66
+0.14 (+1.04 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.05
Now: $13.66
$13.75
50-Day Range
$12.07
MA: $14.56
$18.20
52-Week Range
$11.53
Now: $13.66
$36.49
Volume75,594 shs
Average Volume169,915 shs
Market Capitalization$380.70 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

SQZ Biotechnologies (NYSE:SQZ) Vs. ALVR, KYMR, RGNX, CCCC, REPL, and ALEC

Should you be buying SQZ stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to SQZ Biotechnologies, including AlloVir (ALVR), Kymera Therapeutics (KYMR), REGENXBIO (RGNX), C4 Therapeutics (CCCC), Replimune Group (REPL), and Alector (ALEC).

SQZ Biotechnologies (NYSE:SQZ) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and AlloVir, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQZ Biotechnologies00503.00
AlloVir00403.00

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. AlloVir has a consensus target price of $48.75, suggesting a potential upside of 110.04%. Given SQZ Biotechnologies' higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than AlloVir.

Valuation and Earnings

This table compares SQZ Biotechnologies and AlloVir's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ BiotechnologiesN/AN/AN/AN/AN/A
AlloVirN/AN/AN/AN/AN/A

Insider and Institutional Ownership

32.1% of AlloVir shares are owned by institutional investors. 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SQZ Biotechnologies and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQZ BiotechnologiesN/AN/AN/A
AlloVirN/AN/AN/A

SQZ Biotechnologies (NYSE:SQZ) and Kymera Therapeutics (NASDAQ:KYMR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and Kymera Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQZ Biotechnologies00503.00
Kymera Therapeutics02402.67

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. Kymera Therapeutics has a consensus target price of $48.6667, suggesting a potential upside of 45.53%. Given SQZ Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than Kymera Therapeutics.

Valuation and Earnings

This table compares SQZ Biotechnologies and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ BiotechnologiesN/AN/AN/AN/AN/A
Kymera TherapeuticsN/AN/AN/AN/AN/A

Insider and Institutional Ownership

37.8% of Kymera Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SQZ Biotechnologies and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQZ BiotechnologiesN/AN/AN/A
Kymera TherapeuticsN/AN/AN/A

Summary

SQZ Biotechnologies beats Kymera Therapeutics on 3 of the 4 factors compared between the two stocks.

SQZ Biotechnologies (NYSE:SQZ) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and REGENXBIO, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQZ Biotechnologies00503.00
REGENXBIO02512.88

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. REGENXBIO has a consensus target price of $62.50, suggesting a potential upside of 77.71%. Given SQZ Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than REGENXBIO.

Valuation and Earnings

This table compares SQZ Biotechnologies and REGENXBIO's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ BiotechnologiesN/AN/AN/AN/AN/A
REGENXBIO$35.23 million42.43$-94,730,000.00($3.26)-10.79

SQZ Biotechnologies has higher earnings, but lower revenue than REGENXBIO.

Insider and Institutional Ownership

75.2% of REGENXBIO shares are owned by institutional investors. 14.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SQZ Biotechnologies and REGENXBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQZ BiotechnologiesN/AN/AN/A
REGENXBIO-63.13%-21.73%-18.74%

Summary

SQZ Biotechnologies beats REGENXBIO on 5 of the 9 factors compared between the two stocks.

SQZ Biotechnologies (NYSE:SQZ) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and C4 Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQZ Biotechnologies00503.00
C4 Therapeutics00303.00

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. C4 Therapeutics has a consensus target price of $44.50, suggesting a potential upside of 36.25%. Given SQZ Biotechnologies' higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than C4 Therapeutics.

Valuation and Earnings

This table compares SQZ Biotechnologies and C4 Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ BiotechnologiesN/AN/AN/AN/AN/A
C4 TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares SQZ Biotechnologies and C4 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQZ BiotechnologiesN/AN/AN/A
C4 TherapeuticsN/AN/AN/A

Summary

SQZ Biotechnologies beats C4 Therapeutics on 2 of the 2 factors compared between the two stocks.

SQZ Biotechnologies (NYSE:SQZ) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Profitability

This table compares SQZ Biotechnologies and Replimune Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQZ BiotechnologiesN/AN/AN/A
Replimune GroupN/A-30.23%-24.66%

Insider and Institutional Ownership

55.8% of Replimune Group shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for SQZ Biotechnologies and Replimune Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQZ Biotechnologies00503.00
Replimune Group00903.00

SQZ Biotechnologies currently has a consensus target price of $38.3333, suggesting a potential upside of 180.62%. Replimune Group has a consensus target price of $56.00, suggesting a potential upside of 86.23%. Given SQZ Biotechnologies' higher probable upside, analysts clearly believe SQZ Biotechnologies is more favorable than Replimune Group.

Valuation and Earnings

This table compares SQZ Biotechnologies and Replimune Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ BiotechnologiesN/AN/AN/AN/AN/A
Replimune GroupN/AN/A$-52,630,000.00($1.54)-19.53

SQZ Biotechnologies (NYSE:SQZ) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares SQZ Biotechnologies and Alector's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQZ BiotechnologiesN/AN/AN/A
Alector-757.78%-53.86%-31.44%

Insider & Institutional Ownership

61.5% of Alector shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for SQZ Biotechnologies and Alector, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQZ Biotechnologies00503.00
Alector00503.00

SQZ Biotechnologies presently has a consensus price target of $38.3333, suggesting a potential upside of 180.62%. Alector has a consensus price target of $33.6667, suggesting a potential upside of 93.82%. Given SQZ Biotechnologies' higher probable upside, equities research analysts clearly believe SQZ Biotechnologies is more favorable than Alector.

Valuation & Earnings

This table compares SQZ Biotechnologies and Alector's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ BiotechnologiesN/AN/AN/AN/AN/A
Alector$21.22 million65.14$-105,390,000.00($1.71)-10.16

SQZ Biotechnologies has higher earnings, but lower revenue than Alector.

Summary

SQZ Biotechnologies beats Alector on 4 of the 7 factors compared between the two stocks.


SQZ Biotechnologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AlloVir logo
ALVR
AlloVir
1.4$23.21+5.2%$1.51 billionN/A0.00Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$33.44+4.6%$1.50 billionN/A0.00News Coverage
Gap Down
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.17+0.0%$1.49 billion$35.23 million-14.18News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.66+3.2%$1.41 billionN/A0.00Insider Selling
High Trading Volume
News Coverage
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$30.07+1.9%$1.40 billionN/A-16.99
Alector logo
ALEC
Alector
1.3$17.37+13.0%$1.38 billion$21.22 million-7.79Insider Selling
Gap Down
Ocugen logo
OCGN
Ocugen
1.1$6.96+0.7%$1.31 billionN/A-4.70Gap Up
Translate Bio logo
TBIO
Translate Bio
1.6$17.26+2.1%$1.30 billion$7.80 million-16.13
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.77+3.1%$1.15 billionN/A-2.98Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.90+0.9%$1.15 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.51+0.6%$1.10 billion$32.16 million-9.67Analyst Upgrade
News Coverage
Curis logo
CRIS
Curis
1.3$11.50+2.9%$1.05 billion$10 million-14.02Gap Down
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.22+2.7%$1.04 billionN/A0.00
Scholar Rock logo
SRRK
Scholar Rock
1.5$29.94+6.2%$1.03 billion$20.49 million-12.42Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.95+1.1%$1.02 billion$356.07 million6.84
Cortexyme logo
CRTX
Cortexyme
1.3$33.59+6.9%$992.65 millionN/A-14.00Gap Down
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.10+5.8%$922.43 million$42.74 million-223.33Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.63+0.9%$890.08 millionN/A-4.07
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.08+6.9%$887.99 million$250,000.00-7.15News Coverage
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.83+0.7%$883.45 million$69.89 million-4.49
Passage Bio logo
PASG
Passage Bio
1.8$16.34+4.4%$879.60 millionN/A0.00News Coverage
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.92+1.6%$852.18 million$22.99 million-10.60News Coverage
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.02+2.8%$839.78 millionN/A-9.10News Coverage
Gap Down
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.73+3.7%$832.47 million$2.51 million-4.08Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.47+5.4%$818.93 millionN/A0.00Lockup Expiration
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$21.19+6.0%$800.16 millionN/A0.00Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$5.05+1.6%$785.11 million$1.12 million-5.10
Inhibrx logo
INBX
Inhibrx
1.6$20.50+0.4%$773.83 millionN/A0.00
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$22.67+0.3%$734.76 million$5.78 million-10.64
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.08+2.3%$708.25 millionN/A0.00Analyst Upgrade
News Coverage
Gap Up
Vaxart logo
VXRT
Vaxart
1.3$5.53+2.5%$651.25 million$9.86 million-9.37Gap Down
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.74+3.3%$630.67 million$14.75 million-2.46
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.35+3.3%$590.92 million$13.29 million-9.47News Coverage
Gap Down
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.56+1.2%$585.57 millionN/A0.00Analyst Downgrade
Lockup Expiration
Compugen logo
CGEN
Compugen
1.4$8.42+0.0%$576.10 million$17.80 million-22.76Analyst Report
Analyst Revision
Agenus logo
AGEN
Agenus
1.6$2.79+0.0%$570.05 million$150.05 million-2.56
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.21+3.1%$556.83 millionN/A-2.53Gap Down
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.90+0.6%$552.76 millionN/A-1.30Gap Down
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.48+2.5%$530.64 millionN/A-5.90Gap Down
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.60+3.6%$490.08 million$22.24 million-4.28Gap Down
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$13.23+5.1%$474.60 millionN/A0.00Analyst Report
Gap Down
AVROBIO logo
AVRO
AVROBIO
1.7$11.32+2.5%$471.16 millionN/A-3.43News Coverage
Gap Down
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.25+1.5%$466.41 millionN/A-8.20
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$9.10+1.4%$445.46 million$4.36 million-3.18Analyst Upgrade
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.78+6.6%$443.95 million$147.87 million-3.25Gap Down
Opthea logo
OPT
Opthea
1.5$9.66+1.2%$419.80 millionN/A0.00Lockup Expiration
Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$9.51+6.4%$397.95 millionN/A0.00Analyst Report
Gap Down
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$2.19+2.7%$380.20 million$8.15 million-1.75
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.27+2.3%$348.11 million$250,000.00-3.31News Coverage
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.49+6.2%$340.69 millionN/A0.00Lockup Expiration
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.